Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Simponi, Simponi Aria (Golimumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a ...

Simponi works by blocking tumor necrosis factor (TNF), which plays an important role in causing abnormal inflammatory and immune responses. Previously approved to treat rheumatoid arthritis, psoriatic ...

Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition. “Ulcerative colitis is a complex, lifelong ...

If needed, Simponi Aria may be stored at room temperature up to 77⁰F (25⁰C) for a maximum single period of 30 days in the original carton to protect from light. Once Simponi Aria has been stored at ...

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid ...

REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients ...

Johnson & Johnson is hoping to get a new indication for its human monoclonal antibody Simponi, the rights to which are being fought over with Merck & Co, from the regulator in the USA. Johnson & ...